Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Application of gypenoside-XLIX to preparation of medicine for improving liver fat metabolism

A technology of gypenoside and fat metabolism, which is applied in the field of biomedicine to achieve the effects of reducing content, improving liver fat metabolism disorders, and reducing fat accumulation

Active Publication Date: 2020-06-09
SHANDONG NEWTIME PHARMA
View PDF5 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

So far, there has been no research on the effects of gypenoside XLIX on improving liver fat metabolism and preventing non-alcoholic fatty liver

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of gypenoside-XLIX to preparation of medicine for improving liver fat metabolism
  • Application of gypenoside-XLIX to preparation of medicine for improving liver fat metabolism
  • Application of gypenoside-XLIX to preparation of medicine for improving liver fat metabolism

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0036] Example 1 Establishment and Treatment of Nonalcoholic Fatty Liver Cell Model

[0037] At present, animal models are often used in the research of non-alcoholic fatty liver disease (NAFLD), but animal models have unfavorable factors such as large individual differences, many influencing factors, and difficult control of experimental conditions, while cell models can better overcome the above factors , to study the cellular mechanism of non-alcoholic fatty liver disease (NAFLD) in a targeted manner, and can further shorten the process of drug intervention, so in scientific research practice, especially in the screening of therapeutic drugs for non-alcoholic fatty liver disease (NAFLD) On the one hand, cell models have been paid more and more attention to and applied by researchers, providing a new promising option for the prevention and treatment of nonalcoholic fatty liver disease (NAFLD).

[0038] Hepatocytes are cells with a high degree of differentiation. Once they lo...

Embodiment 2

[0047] Example 2 Effect of Gypenoside XLIX on Hepatocyte TG Content

[0048] According to the instructions provided by the triglyceride (TG) kit, first collect the cells, add the lysate, shake and lyse, place on ice for 10 minutes, take out an appropriate amount of liquid to measure the protein concentration (BCA method), and heat the remaining liquid at 70°C 10 minutes, then centrifuge at 2000 rpm for 5 minutes at room temperature, take the supernatant and measure the TG content by the glycerol-3-phosphate oxidase method: add the sample according to the reagent instructions, mix well, react at 37°C for 10 minutes, adjust the blank tube to zero, and then measure The optical density (OD) value of each tube was used to draw a standard curve and calculate the TG concentration. Finally, the total protein concentration was used to correct the TG content. The obtained test results were as follows: figure 1 shown.

[0049] Depend on figure 1 The results showed that compared with th...

Embodiment 3

[0050] Example 3 Effect of Gypenoside XLIX on Fat Accumulation in Hepatocytes

[0051] Effect of Gypenoside XLIX on Fat Accumulation in Hepatocytes Using Oil Red O Staining

[0052] Preparation of oil red O working solution: oil red O was dissolved in isopropanol to prepare 0.5% oil red O stock solution, mixed the stock solution with distilled water at a ratio of 6:4 and filtered twice until the liquid was clear to obtain oil red O working fluid.

[0053] The mouse liver primary cells were inoculated into 12-well plates, and after incubation for 24 hours, they were divided into plates and treated according to the above method, and were divided into DMSO+BSA group, DMSO+PA group, XLIX+BSA group, XLIX+PA group, each group Add the corresponding treatment, the added medium is the same as the above, continue to incubate for 24 hours, remove the culture medium, stain the cells of each group with Oil Red O working solution for 30 minutes, wash with distilled water twice, observe the...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides application of gypenoside-XLIX to preparation of medicine for improving the liver fat metabolism. The medicine is used for preventing and / or treating relevant diseases caused byliver fat metabolism disorder. By building a cell model of non-alcoholic fatty liver diseases, the effect of the gypenoside-XLIX of obviously improving the liver fat metabolism is proved. Through experiments, the effects that the gypenoside-XLIX can be used for reducing the content of triglyceride in the liver cells, reducing the fat accumulation in the liver cells, and regulating down the SCD1 transcriptional level expression to relieve the liver fat metabolism disorder are discovered. Therefore, the gypenoside-XLIX has an important effect on the prevention and treatment of the non-alcoholicfatty liver diseases.

Description

technical field [0001] The invention relates to the application of gypenoside XLIX in improving liver and liver fat metabolism and preventing and treating related diseases caused by liver and liver fat metabolism disorder, belonging to the technical field of biomedicine. Background technique [0002] The liver is the main place for fat synthesis, operation and utilization. The liver can continuously synthesize the fatty acids entering the liver into triglycerides, and the synthesized triglycerides are quickly released into the blood in the form of lipoproteins. When there is too much stored fat, the level of free fatty acids in plasma rises, and the synthesis of triglyceride in the liver exceeds the synthesis of lipoprotein as a tool for operation, that is, the synthesis and operation of fat in the liver are out of balance, which can make the fat in the liver accumulation to form fatty liver. [0003] Nonalcoholic fatty liver disease (NAFLD) is a clinicopathological syndro...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/704A61P1/16A61P3/04A61P3/00
CPCA61K31/704A61P1/16A61P3/00A61P3/04
Inventor 赵家军高聆陈文斌石书龙
Owner SHANDONG NEWTIME PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products